ARTICLE | Top Story
Genzyme up on Renagel data
July 29, 2005 12:27 AM UTC
GENZ was up $4.70 to $75.20 on Thursday after announcing data from the three-year post-marketing DCOR trial comparing Renagel sevelamer to calcium-based phosphate buffers in patients with chronic kidn...